WO2011158960A1 - Method for selecting human induced pluripotent stem cells - Google Patents
Method for selecting human induced pluripotent stem cells Download PDFInfo
- Publication number
- WO2011158960A1 WO2011158960A1 PCT/JP2011/064195 JP2011064195W WO2011158960A1 WO 2011158960 A1 WO2011158960 A1 WO 2011158960A1 JP 2011064195 W JP2011064195 W JP 2011064195W WO 2011158960 A1 WO2011158960 A1 WO 2011158960A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- differentiation
- human ips
- induction
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
Definitions
- the present invention relates to a method for selecting human induced pluripotent stem (iPS) cells which can be safely used for transplantation. More particularly, the present invention relates to a method for selecting human iPS cells having reduced differentiation resistance, comprising the steps of: (1) inducing differentiation of human iPS cells; (2) detecting remaining undifferentiated cells after the step (1); and (3) selecting human iPS cells whose rate of remaining
- undifferentiated cells detected in step (2) is equivalent to or not more than that of control cells.
- iPS cells are established by introduction of reprogramming-inducing genes into human skin-derived fibroblasts (WO 2007/069666 Al , Takahashi, K. et al., Cell, 131: 861-872 (2007), WO
- iPS cells can be made to differentiate into cells of various tissues after being established from cells derived from the patient to be treated, they are expected to be useful as a graft material which does not cause the rejection reaction.
- mice after inducing differentiation into neural progenitor cells, some mouse iPS cells remain undifferentiated and cause tumor formation when they are transplanted into mice (Miura K. et al., Nat Biotechnol., 27: 743-745 (2009)). Such remaining of undifferentiated cells is considered to be due to properties of individual iPS cell lines. Further, since many cell lines are established at once by the process of establishing iPS cells, a simple method for selecting iPS cell lines suitable for transplantation among many iPS cell lines has been demanded.
- An object of the present invention is to efficiently select safe human iPS cells suitable for clinical application. Specifically, an object of the present invention is to provide a method for selectively eliminating human iPS cells, in which the ratio of differentiation-resistant cells maintaining pluripotency after differentiation induction is high, from human iPS cells.
- the inventors of the present invention induced differentiation of human iPS cells under an appropriate condition and then observed remaining undifferentiated cells which formed colonies culturing under an undifferentiation-maintaining condition or expressed Oct3/4 or TRA-1-60. As a result, it was found that the ratio of remaining undifferentiated cells was different among cell lines. For example, the number of colonies formed was low for human embryonic stem cells (ES cells) cultured under the above-described condition, while the number of colonies formed was large in some of human iPS cells.
- ES cells human embryonic stem cells
- human iPS cells having reduced differentiation resistance can be selected by inducing differentiation of human iPS cells under an appropriate condition and detecting remaining undifferentiated cells and selecting human iPS cells for which the number is low, thereby completed the present invention.
- the present invention is as follows.
- a method for selecting human induced pluripotent stem (iPS) cells having reduced differentiation resistance comprising the steps of:
- step (3) selecting human iPS cells whose rate of remaining undifferentiated cells detected in step (2) is equivalent to or not more than that of control cells.
- control cells are human embryonic stem cells.
- control cells are human iPS cells which is known to have reduced differentiation resistance.
- differentiation resistance which are suitable for differentiation into cells to be used for transplantation, can be selected. Therefore, the present invention is very useful for application of human iPS cells to regenerative medicine.
- Fig. 1 shows the protocol of the experiment.
- Fig. 2 shows the state of colonies observed with crystal violet staining, after differentiation induction and culturing under an undifferentiation-maintaining condition (photograph).
- Fig. 3 shows the numbers of colonies observed after culturing the respective
- a represents the results obtained for human iPS cell lines established with 4 factors (OCT3/4, SOX2, KLF4 and c-MYC).
- b represents the results obtained for human iPS cell lines established with 3 factors (OCT3/4, SOX2 and KLF4).
- c represents the results obtained for human iPS cell lines established with 4 factors (OCT3/4, SOX2, KLF4 and c-MYC) from cells produced by differentiation induction of KhESl .
- KhESl and KhES3 are ES cells used as controls.
- 201B2 and 201B7 are human iPS cells established with the 4 factors.
- 201B2-MF is a normal karyotype cell line selected from subclones of 201B2.
- Fig. 4 shows the Oct3/4 positive cell content rate after the neural
- Fig. 5 shows the TRA-1-60 positive cell content rate after the neural differentiation from various clones of iPS cells or ES cells
- a represent the results obtained for CB-RV4F-2 subclones
- b represent the results obtained for DP-EP6F- 1 subclones
- c represent the results obtained for FB-RV3F-4 subclones
- d represent the results obtained for FB-RV4F-5 subclones.
- the present invention provides a method for selecting human iPS cells (human iPS cells) having reduced differentiation resistance, by inducing
- human iPS cells having reduced differentiation resistance means human iPS cells in which the ratio of cells showing differentiation resistance is small.
- cells showing differentiation resistance herein means pluripotent stem cells in which the "self-renewal capacity” is abnormally strong among the two properties of stem cells, the "differentiation capacity” and the “self-renewal capacity”. That is, the term means pluripotent stem cells have high risk of formation of a tumor because these cells still maintain pluripotency by self-renewal when they are induced to differentiate into the cells of interest and transplanted. In cases where such human iPS cells, in which the ratio of cells showing differentiation resistance is high, are induced to differentiate into the cells of interest and
- these cells may form a tumor with a possibility higher than that usually observed in cases where normal embryonic stem cells (ES cells) are used.
- ES cells normal embryonic stem cells
- differentiation resistance is small, so that the risk of formation of a tumor is small when these cells are induced to differentiate into the cells of interest and transplanted to a host.
- the human iPS cells which can be used for the selection method of the present invention are stem cells having pluripotency that allows differentiation of the cells into any cells existing in body and also having the self-renewal capacity.
- Induced pluripotent stem (iPS) cells are artificial stem cells derived from somatic cells, which can be prepared by introducing certain particular nuclear reprogramming substances to somatic cells in the form of DNA or protein, and have properties almost equivalent to those of ES cells, such as pluripotency and growth capacity by self-renewal (K. Takahashi and S. Yamanaka (2006) Cell, 126: 663-676; K. Takahashi et al. (2007) Cell, 131 : 861-872; J. Yu et al. (2007) Science, 318: 1917- 1920; M. Nakagawa et al. (2008) Nat. Biotechnol, 26: 101-106; WO 2007/069666).
- the nuclear reprogramming substances may be genes specifically expressed in ES cells, or genes or gene products thereof that play important roles for maintaining the undifferentiated state of ES cells.
- the nuclear reprogramming substances are not restricted, and examples thereof include Oct3/4, Klf4, lfl , lf2, Klf5, Sox2, Soxl , Sox3, Soxl5, Soxl 7, Soxl 8, c-Myc, L-Myc, N-Myc, TERT, SV40 Large T antigen, HPV16 E6, HPV16 E7, Bmil, Lin28, Lin28b, Nanog, Salll, Sall4, Glisl, Esrrb,Esrrg, Nr5a2 and Tbx3.
- These reprogramming substances may be used in combination when iPS cells are to be established.
- the combination may contain at least one, two or three of the above reprogramming substances, and the combination preferably contains four of the above reprogramming substances.
- the information on the nucleotide sequences of mouse and human cDNAs of the above-described respective nuclear reprogramming substances, and the amino acid sequences of the proteins encoded by the cDNAs can be obtained by referring to the NCBI (National Center for Biotechnology Information) accession numbers described in WO 2007/069666. Further, the information on the mouse and human cDNA sequences and amino acid sequences of L-Myc, Lin28, Lin28b, Esrrb and Esrrg can be obtained by referring to the NCBI accession numbers described below. Those skilled in the art can prepare desired nuclear reprogramming substances by a conventional method based on the information on the cDNA sequences or amino acid sequences.
- nuclear reprogramming substances may be introduced into somatic cells in the form of protein by a method such as lipofection, binding to a cell membrane-permeable peptide, or microinjection, or in the form of DNA by a method such as use of a vector including a virus, plasmid and artificial chromosome;
- virus vector examples include retrovirus vectors, lentivirus vectors (these are described in Cell, 126, pp.663-676, 2006; Cell, 131, pp.861-872, 2007; and Science, 318, pp.1917-1920, 2007), adenovirus vectors ⁇ Science, 322, 945-949, 2008), adeno-associated virus vectors and Sendai virus vectors ⁇ Proc Jpn Acad Ser B Phys Biol Sci. 85, 348-62, 2009).
- the artificial chromosome vector examples include human artificial chromosomes (HACs), yeast artificial chromosomes (YACs) and bacterial artificial chromosomes (BACs, PACs) (WO 2010/038904).
- HACs human artificial chromosomes
- YACs yeast artificial chromosomes
- BACs, PACs bacterial artificial chromosomes
- plasmid examples include plasmids for mammalian cells ⁇ Science, 322:949-953, 2008).
- the vectors may contain a regulatory sequence(s) such as a promoter, enhancer, ribosome binding sequence, terminator and/or polyadenylation site.
- promoter to be used examples include the EFla promoter, CAG promoter, SRa promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, MoMuLV (Moloney murine leukemia virus) LTR and HSV-TK (herpes simplex virus thymidine kinase) promoter.
- the EFla promoter the EFla promoter
- CAG promoter SRa promoter
- SV40 promoter examples include the promoter to be used.
- LTR promoter examples include the EFla promoter, CAG promoter, SRa promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, MoMuLV (Moloney murine leukemia virus) LTR and HSV-TK (herpes simplex virus thymidine kinase
- the vectors may further contain, as required, a sequence of a selection marker such as a drug resistance gene (e.g., kanamycin-resistant gene, ampicillin-resistant gene or puromycin-resistant gene), thymidine kinase gene or diphtheria toxin gene; a gene sequence of a reporter such as the green-fluorescent protein (GFP), ⁇ -glucuronidase (GUS) or FLAG; or the like.
- a selection marker such as a drug resistance gene (e.g., kanamycin-resistant gene, ampicillin-resistant gene or puromycin-resistant gene), thymidine kinase gene or diphtheria toxin gene
- a gene sequence of a reporter such as the green-fluorescent protein (GFP), ⁇ -glucuronidase (GUS) or FLAG; or the like.
- GFP green-fluorescent protein
- GUS ⁇ -glucuronidase
- the vector may have loxP sequences in the upstream and the downstream of these sequences.
- a method may be employed wherein, after incorporation of the transgene(s) into a chromosome(s) using a transposon, transposase is allowed to act on the cells using a plasmid vector or an adenovirus vector, thereby completely removing the transgene(s) into a chromosome(s) using a transposon, transposase is allowed to act on the cells using a plasmid vector or an adenovirus vector, thereby completely removing the
- Preferred examples of the transposon include piggyBac, which is a transposon derived from a lepidopteran insect (Kaji, K. et al., Nature, 458: 771-775 (2009); Woltjen et al., Nature, 458: 766-770 (2009); WO 2010/012077).
- the vector may contain the origin of lymphotrophic herpes virus, BK virus or Bovine papillomavirus and sequences involved in their replication, such that the vector can replicate without incorporation into the chromosome and exist episomally.
- Examples of such a vector include vectors containing EBNA-1 and oriP sequences and vectors containing Large T and SV40ori sequences (WO 2009/1 15295; WO 2009/157201 ; WO 2009/149233). Further, in order to introduce plural nuclear reprogramming substances at the same time, an expression vector which allows polycistronic expression may be used. In order to allow polycistronic expression, the sequences encoding the genes may be linked to each other via IRS or the foot-and-mouth disease virus (FMDV) 2A coding region (Science, 322:949-953, 2008; WO 2009/092042 2009/152529).
- IRS foot-and-mouth disease virus
- histone deacetylase (HDAC) inhibitors for example, low molecular inhibitors such as valproic acid (VP A) (Nat. Biotechnol, 26(7): 795-797 (2008)), trichostatin A, sodium butyrate, MCI 293 and M344; and nucleic acid-type expression inhibitors such as siRNAs and shRNAs against HDAC (e.g., HDAC1 siRNA Smartpool (registered trademark) (Millipore) and HuSH 29mer shRNA Constructs against HDAC1 (OriGene))], DNA methyltransferase inhibitors (e.g., 5'- azacytidine) (Nat. Biotechnol, 26(7): 795-797 (2008)), G9a histone deacetylase (HDAC) inhibitors [for example, low molecular inhibitors such as valproic acid (VP A) (Nat. Biotechnol, 26(7): 795-797 (2008)), trichostatin A, sodium butyrate
- methyltransferase inhibitors for example, low molecular inhibitors such as BIX- 01294 (Cell Stem Cell, 2: 525-528 (2008)); and nucleic acid-type expression inhibitors such as siRNAs and shRNAs against G9a (e.g., G9a siRNA (human) (Santa Cruz Biotechnology))], L-channel calcium agonists (e.g., Bayk8644) (Cell Stem Cell, 3, 568-574 (2008)), p53 inhibitors [e.g., siRNAs and shRNAs against p53 (Cell Stem Cell, 3, 475-479 (2008))], Wnt Signaling activators (e.g., soluble Wnt3a) (Cell Stem Cell, 3, 132-135 (2008)), growth factors such as LIF, SCF and bFGF, ALK5 inhibitors (e.g., SB431542) (Nat Methods, 6: 805-8 (2009)), mitogen- activated protein kinase signaling inhibitors, glycogen synth
- Examples of the culture medium for induction of the iPS cells include (1) DMEM, DMEM/F12 and DME media supplemented with 10 to 15% FBS (these media may further contain LIF, penicillin/streptomycin, puromycin, L-glutamine, non-essential amino acids, ⁇ -mercaptoethanol and/or the like, as appropriate); (2) culture media for ES cells containing bFGF or SCF, for example, culture media for mouse ES cells (e.g., TX-WES medium, Thromb-X) and culture media for primate ES cells (e.g., culture medium for primate (human and monkey) ES cells,
- Examples of the culture method include a method wherein somatic cells and nuclear reprogramming substances (DNAs or proteins) are brought into contact with each other at 37°C in the presence of 5% C0 2 on DMEM or DMEM/F12 medium supplemented with 10% FBS, and the cells are cultured for about 4 to 7 days, followed by replating the cells on feeder cells (e.g., mitomycin C-treated STO cells, SNL cells or the like) and starting culture in a bFGF-containing culture medium for primate ES cells about 10 days after the contact between the somatic cells and the reprogramming substances, thereby allowing iPS-like colonies to appear about 30 to about 45 days after the contact, or later.
- feeder cells e.g., mitomycin C-treated STO cells, SNL cells or the like
- a bFGF-containing culture medium for primate ES cells about 10 days after the contact between the somatic cells and the reprogramming substances, thereby allowing iPS-like colonies to appear about 30
- the somatic cells may be cultured on feeder cells (e.g., mitomycin C-treated STO cells or SNL cells) in DMEM medium supplemented with 10% FBS (which may further contain LIF, penicillin/streptomycin, puromycin, L- glutamine, non-essential amino acids, ⁇ -mercaptoethanol and/or the like, as appropriate), thereby allowing ES-like colonies to appear after about 25 to about 30 days of the culture, or later.
- feeder cells e.g., mitomycin C-treated STO cells or SNL cells
- FBS which may further contain LIF, penicillin/streptomycin, puromycin, L- glutamine, non-essential amino acids, ⁇ -mercaptoethanol and/or the like, as appropriate
- the culture medium is replaced with a fresh culture medium once a day from Day 2 of the culture.
- the number of the somatic cells used for nuclear reprogramming is not restricted, and usually within the range of about 5 x 10 to about 5x 10 cells per 100-cm area on the culture dish.
- cells expressing the marker gene can be selected by culturing the cells in a culture medium (selection medium) containing the corresponding drug.
- Cells expressing a marker gene can be detected by observation under a fluorescence microscope in cases where the marker gene is the gene of a fluorescent protein; by adding a luminescent substrate in cases where the marker gene is the gene of luciferase; or by adding a coloring substrate in cases where the marker gene is the gene of a coloring enzyme.
- the term "somatic cells” used in the present description means cells derived from human, and examples thereof include epithelial cells which are keratinized (e.g., keratinized epidermal cells), mucosal epithelial cells (e.g., epithelial cells of the lingual surface), epithelial cells of exocrine glands (e.g., mammary cells), hormone- secreting cells (e.g., adrenomedullary cells), cells for metabolism and storage (e.g., hepatic cells), luminal epithelial cells constituting boundary surfaces (e.g., type I alveolar cells), luminal epithelial cells in the closed circulatory system (e.g., vascular endothelial cells), ciliated cells having a carrying capacity (e.g., tracheal epithelial cells), extracellular matrix-secreting cells (e.g., fibroblasts), contractile cells (e.g., smooth muscle cells), cells involved in the blood system and
- undifferentiated progenitor cells including somatic stem cells
- terminally-differentiated mature cells may be used as the source of the somatic cells in the present invention.
- undifferentiated progenitor cells include tissue stem cells (somatic stem cells) such as neural stem cells, hematopoietic stem cells, mesenchymal stem cells and dental pulp stem cells.
- “Differentiation induction” in the present invention includes not only differentiation into particular organ cells or progenitor cells thereof, but also differentiation into cell groups containing many kinds of cells such as endodermal cells, mesodermal cells and ectodermal cells.
- organs into which differentiation is to be induced include, but are not limited to, skin, blood vessel, cornea, kidney, heart, liver, umbilical cord, intestine, nerve, lung, placenta, pancreas, brain, periphery of limbs, and retina.
- the method of such differentiation induction is not limited, and methods well-known to those skilled in the art may be used.
- Examples of the method include the method described in JP 2002-291469 A, which is a method for differentiation induction into neural stem cells; the method described in JP 2004-121 165 A, which is a method for differentiation induction into pancreatic stem-like cells; and the method described in JP2003-505006, which is a method for differentiation induction into hematopoietic cells. Further examples of the method include the method described in JP2003-523766, which is a method for
- a preferred method for differentiation induction in the present invention is a method for differentiation induction by culture without using feeder cells. More particularly, in this method, the cells are cultured in an arbitrary medium with a coated culture dish for adherent culture or floating culture with formation of embryoid bodies.
- the coating agent include collagen, gelatin, laminin, LIPIDURE (NOF Corporation) and Matrigel (BD), and combinations thereof.
- the coating agent is preferably LIPIDURE (NOF Corporation) or Matrigel (BD).
- culture medium examples include, but are not limited to, Neurobasal medium (Invitrogen), minimum essential medium (MEM), Dulbecco's modified Eagle's medium (DMEM), RPMI1640 medium, 199 medium, F12 medium, and
- the culture medium is preferably the combination of Neurobasal medium, DMEM and F12 medium.
- FBS fetal bovine serum
- albumin albumin
- transferrin fatty acids
- insulin Knockout Serum Replacement
- non-essential amino acids nucleosides
- L- glutamine 2-mercaptoethanol
- progesterone putrescine
- sodium selenite bovine serum albumin fraction V
- B27 supplement Invitrogen
- BMP inhibitor TGF- ⁇ family inhibitor
- a BMP inhibitor having such properties include a compound that inhibits BMP2, BMP4, BMP6 or BMP7 capable of activating
- Dorsomorphin is commercially available from Sigma-Aldrich, for example. Dorsomorphin has biological activity to inhibit the above BMP signaling by inhibiting the binding of BMP to a BMP receptor.
- examples of a BMP I-type receptor kinase inhibitor include LDN-193189 (that is, 4-(6-(4-(piperazin-l- yl)phenyl)pyrazolo[l ,5-a]pyrimidin-3-yl)quinoline) and a derivative thereof (Yu PB et al. Nat Med, 14: 1363-9, 2008).
- examples of a TGF- ⁇ family inhibitor include SB431542, SB202190 (R. K. Lindemann et al., Mol. Cancer 2: 20 (2003)),
- LY2109761, LY364947, and LY580276 (Lilly Research Laboratories), and A-83- 01(WO 2009146408). SB431542 or A-83-01 is preferred.
- ROCK inhibitor examples include Y-27632 (Calbiochem; water soluble) and Fasudil (HA1 077:
- differentiation induction is not restricted, and examples thereof include 1000000 to 3000000 cells/33.5 mm-dish (6-well plate), such as about 2500000 cells/33.5 mm- dish, about 2000000 cells/33.5 mm-dish, about 1500000 cells/33.5 mm-dish or about 1000000 cells/33.5 mm-dish.
- the cell density is particularly preferably about 2500000 cells/33.5 mm-dish (6-well plate).
- the period of differentiation culture is not restricted, and examples thereof include 2 to 14 days (e.g., 14days, 12days, 10 days, 8 days, 6 days, 4 days or 2 days). In the case of using N2B27 medium, the period of differentiation culture is preferably about 5 days. In another embodiment of using culture medium comprising BMP inhibitor and TGF- ⁇ family inhibitor, the period of differentiation culture is preferably about 14 days.
- the undifferentiation-maintaining condition in the present invention is a condition under which human iPS cells can grow while maintaining their
- pluripotency examples thereof include culturing cells together with feeder cells.
- the culture medium is not restricted, and examples thereof include minimum essential medium (MEM), Dulbecco's modified Eagle's medium (DMEM),
- RPMI 1640 medium 199 medium, F 12 medium or combinations of these, supplemented with 20% SR, to which L-glutamine, non-essential amino acids, nucleosides, and/or 2-mercaptoethanol are added.
- LIF, SCF or bFGF; 2i an inhibitor of mitogen-activated protein kinase signalling and glycogen synthase kinase-3, PloS Biology, 6(10), 2237-2247 (2008)); or the like may be added to the culture medium.
- the cells When the culture condition is changed from the differentiation inducing condition to the undifferentiation maintaining condition, the cells may be detached from the dish and then plated again. When this replating is carried out, only live cells may be selected.
- the method of selection of the live cells is not restricted, and it may be carried out by, for example, staining the cells with propidium iodide (PI) and separating/purifying unstained cells by FACS or the like.
- the culture period under the undifferentiation maintaining condition is not restricted as long as colonies can be observed during the period, and preferably 10 days to 20 days, more preferably about 14 days.
- maintaining condition is not restricted, and examples thereof include 1000000 to 2500000 cells/33.5 mm-dish (6-well plate), such as about 2500000 cells/33.5 mm- dish, about 2000000 cells/33.5 mm-dish, about 1500000 cells/33.5 mm-dish or about 1000000 cells/33.5 mm-dish.
- the cell density is preferably about 1500000 cells/33.5 mm-dish (6-well plate).
- this step of culturing under undifferentiation-maintaining condition may be skipped.
- undifferentiated cells After the induction of differentiation of the cells, remaining undifferentiated cells can be detected using properties specific to the undifferentiated cells.
- Examples of such specific properties include formation of colonies after culturing under the undifferentiation maintaining condition as described above, expression of undifferentiation-specific antigens and expression of undifferentiation-specific genes.
- the undifferentiation-specific antigens are not restricted, and may be selected from, for example, the group consisting of SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81.
- Examples of the undifferentiation-specific genes include the genes such as Oct3/4, Nanog and Rexl described in WO2007/069666.
- the detection of remaining undifferentiated is performed by measuring number of undifferentiated cells and number of total cells. More preferably, the detection is ratio of number of undifferentiated cells to number of total cells.
- colonies In view of simplicity and providing sufficient sensitivity and specificity, it is preferred to observe formation of colonies to detect the generation of undifferentiated cells.
- the method of measurement of colonies is not restricted, and for example, the colonies are counted under the microscope and the counted number is used for the evaluation.
- a staining such as crystal violet staining may be used. This measurement may be carried out either mechanically or visually.
- cells expressing an undifferentiation-specific antigen or gene may be evaluated as the number of cells expressing the antigen or gene, using FACS.
- the method for detecting expression of an undifferentiation-specific gene is not restricted, and examples thereof include methods for detecting its transcription product (hnRNA, mRNA or the like), such as the PCR method, LAMP method and Northern hybridization method; and methods for detecting its translation product (peptide, modified peptide or the like), such as the RIA method, IRMA method, EIA method, ELISA method, LPIA method, CLIA method and immunoblotting.
- undifferentiated cells are preferably evaluated as the number of colonies formed; the number of undifferentiation-specific-antigen-positive cells or the number of cells expressing an undifferentiation-specific gene; or the amount of an undifferentiation- specific antigen or the expression level of an undifferentiation-specific gene in a certain number of cells.
- the ratio of undifferentiated cells is preferably not more than 5%, 1%, 0.1%, more preferably not more than 1% with respect to the number of the cells cultured under an undifferentiation maintaining condition.
- the number of undifferentiated cells is especially preferably 0.
- human iPS cells having reduced differentiation resistance when the human iPS cells having reduced differentiation resistance are selected, human iPS cells, in which the degree of remaining undifferentiated cells is not more than that of undifferentiated cells obtained by inducing differentiation of ES cells and culturing the ES cells under an undifferentiation-maintaining condition, may be selected as the human iPS cells having reduced differentiation resistance.
- the ratio in an available arbitrary human iPS cell line in which the state of differentiation resistance (ratio of undifferentiated cells) is preliminarily determined is investigated to prepare Table 1 , and a value preliminarily set such that both the sensitivity and the specificity shown in Table 1 are not less than 0.9, preferably not less than 0.95, more preferably not less than 0.99 may be used as the control value. Both of the sensitivity and specificity values are still more preferably 1.
- the fact that both the sensitivity and the specificity are 1 means that the control value is ideal since there is neither false positive nor false negative at all. [Table 1]
- Human iPS cells were prepared from fibroblasts or dental pulp stem cells using 4 factors (OCT3/4, SOX2, KLF4 and c-MYC) or 3 factors (OCT3/4, SOX2 and KLF4) by conventional methods (Takahashi K, et al. Cell. 131 :861 -72, 2007;
- WO 2009/057831 22 lines of iPS cells such as 201 B2 and 201 B7 were used.
- 22 lines of iPS cells such as 201 B2 and 201 B7 were used.
- 14 lines of iPS cells were used.
- 201B2 shows trisomy of chromosome 12.
- the karyotype of 201 B7 was normal.
- 201B2-MF was established as a clone having the normal karyotype.
- KhESl was cultured in a bFGF-free culture medium in the absence of feeder cells for 5 days, and OCT3/4, SOX2, KLF4 and c-MYC were introduced to the cultured cells by the method described in Takahashi K, et al. Cell. 131 :861 -72, 2007 using a retrovirus, thereby 7 lines were established.
- ES cells, human iPS cells, or iPS cells derived from human ES cells were detached from the culture dish using CTK solution, which is PBS containing 0.1 mg/ml collagenase IV (Invitrogen), 0.25% trypsin (Invitrogen), 0.1 mM CaCl 2 (Nacalai Tesque) and 20% KSR (Invitrogen), and Accutase, and plated on a 6-well plate coated with BD Matrigel (BD) at a density of 2 ⁇ 10 6 cells/well. Subsequently, adherent culture was carried out using N2B27 medium for 5 days. N2B27 medium was prepared by the method described in Ying QL, et al., Nature Biotechnology 21 :183-186, 2003.
- the cells whose differentiation was induced by the method described above were suspended using CTK solution, and plated on SNL cells at a density of 1.5x 10 6 cells/10 cm-dish. Subsequently, the cells were cultured by adherent culture for 14 days using a culture medium for human ES cells, which is DMEM/F12 containing 0.1 mM 2-mercaptoethanol (Sigma), non-essential amino acids (Invitrogen), 5 ng/ml recombinant human basic FGF (Upstate) and 20% KSR.
- a culture medium for human ES cells which is DMEM/F12 containing 0.1 mM 2-mercaptoethanol (Sigma), non-essential amino acids (Invitrogen), 5 ng/ml recombinant human basic FGF (Upstate) and 20% KSR.
- a culture medium for human ES cells which is DMEM/F12 containing 0.1 mM 2-mercaptoethanol (Sigma), non-essential amino acids (Invitrogen), 5 ng
- iPS-KhESl -Fib-4F showed smaller numbers of colonies formed (1 to 6), compared to human ES cells.
- 201B2 having a mutation in the karyotype showed a larger number of colonies compared to human ES cells. That is, 201B2 was revealed to be an iPS cell line showing resistance to differentiation induction.
- KhES-1 , KhES-3 (Suemori H, et al. Biochem Biophys Res Commun. 345:926- 32, 2006) and H9 (Thomson, J. A., et al., Science 282 : 1 145-1 147, 1998) were used as human ES cells.
- CB-RE4F 3 clones of CB-RE4F were prepared from CD34 positive cells contained in cord blood by induction of 4factors (OCT3/4, SOX2, KLF4 and c-MYC) with retrovirus (WO2010/131747).
- the human ES cells and human iPS cells were induced to differentiate into neural cells with modified SFEBq method comprising following steps of:
- CT dissociation solution 0.25% Trypsin, 1 mg/ml Collagenase and KSR 20%, and 1 mM CaCl 2 ) was added to culture dish and all cells were transferred to gelatin coated dish. Then, the adherent cells were discarded. ;
- the dissociated ES cells or iPS cells were transferred to LIPIDURE-COAT PLATE (NOF Corporation) to form embryoid body and cultured with differentiation medium (DMEM/Ham's F12 containing 5% KSR(Invitrogen), 2mM L- glutamine(Invitrogen), MEM-non-essential amino acids solution(Invitrogen), 1 ⁇ 2- mercaptoethanol (2-ME), 10 ⁇ Y27632, 2 ⁇ Dorsomorphin (Sigma) and 10 ⁇ SB431542 (Sigma)) for 3 or 4 days; and
- differentiation medium DMEM/Ham's F12 containing 5% KSR(Invitrogen), 2mM L- glutamine(Invitrogen), MEM-non-essential amino acids solution(Invitrogen), 1 ⁇ 2- mercaptoethanol (2-ME), 10 ⁇ Y27632, 2 ⁇ Dorsomorphin (Sigma) and 10 ⁇ SB431542 (Sigma)
- the obtained neural cells were dissociated and immunostained with Oct3/4 antibody. Then, the content rate of Oct3/4 positive cells was analyzed with flow cytometry. The result is shown in Table 5 and Fig 4. From the above results, it was revealed that 5 clones of human iPS cells (CB-RV4F-2, DP-EP6F-1, FB-RV3F- 3, FB-RV3F-4 and FB-RV4F-5) could be selected as the clones with differentiation resistance. On the other hand, there were 25 clones with low differentiation resistance, whose maximum content rates are not more than 1%.
- KhES-1 , KhES-3 (Suemori H, et al. Biochem Biophys Res Commun. 345:926- 32, 2006) and H9 (Thomson, J. A., et al., Science 282 : 1 145-1147, 1998) were used as human ES cells.
- the human iPS clones (CB-RV4F-2, DP-EP6F-1, FB-RV3F-4 and FB-RV4F- 5) which resisted inducing neural differentiation by modified SFEBq method were subcloned into 15 clones, 15 clones, 10 clones and 12 clones, respectively (see table 6 to 9).
- the neural cells which were produced with above modified SFEBq method from said subclones, parent clones or ES cell lines were dissociated and
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/704,584 US8932857B2 (en) | 2010-06-15 | 2011-06-15 | Method for selecting reduced differentiation resistance human induced pluripotent stem cells |
EP11795862.9A EP2582795B1 (en) | 2010-06-15 | 2011-06-15 | Method for selecting human induced pluripotent stem cells |
JP2012556312A JP5936134B2 (en) | 2010-06-15 | 2011-06-15 | Selection method of human induced pluripotent stem cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35485910P | 2010-06-15 | 2010-06-15 | |
US61/354,859 | 2010-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011158960A1 true WO2011158960A1 (en) | 2011-12-22 |
Family
ID=45348349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/064195 WO2011158960A1 (en) | 2010-06-15 | 2011-06-15 | Method for selecting human induced pluripotent stem cells |
Country Status (4)
Country | Link |
---|---|
US (1) | US8932857B2 (en) |
EP (1) | EP2582795B1 (en) |
JP (1) | JP5936134B2 (en) |
WO (1) | WO2011158960A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013503603A (en) * | 2009-09-02 | 2013-02-04 | 国立大学法人京都大学 | How to select pluripotent stem cells safely |
JP2014523735A (en) * | 2011-07-25 | 2014-09-18 | 国立大学法人京都大学 | Method for selecting induced pluripotent stem cells |
WO2014200114A1 (en) * | 2013-06-11 | 2014-12-18 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
US9005975B2 (en) | 2009-05-29 | 2015-04-14 | Kyoto University | Method for selecting clone of induced pluripotent stem cells |
WO2016090408A1 (en) * | 2014-12-08 | 2016-06-16 | Northern Sydney Local Health District | Compositions and methods for neuronal differentiation of cells |
EP2980207A4 (en) * | 2013-03-25 | 2016-09-07 | Found Biomedical Res & Innov | Cell sorting method |
US10329534B2 (en) | 2010-03-01 | 2019-06-25 | Janssen Biotech, Inc. | Methods for purifying cells derived from pluripotent stem cells |
US10344264B2 (en) | 2012-12-31 | 2019-07-09 | Janssen Biotech, Inc. | Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells |
US10358628B2 (en) | 2011-12-22 | 2019-07-23 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into single hormonal insulin positive cells |
US10377989B2 (en) | 2012-12-31 | 2019-08-13 | Janssen Biotech, Inc. | Methods for suspension cultures of human pluripotent stem cells |
EP3564385A4 (en) * | 2016-12-27 | 2020-08-12 | Sumitomo Chemical Company, Limited | Evaluation method and selection method for induced pluripotent stem cells, and production method for induced pluripotent stem cells |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8642334B2 (en) | 2009-02-17 | 2014-02-04 | Memorial Sloan Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
US11261425B2 (en) * | 2009-08-12 | 2022-03-01 | Kyoto University | Method for inducing differentiation of pluripotent stem cells into neural precursor cells |
CN102559587A (en) * | 2010-12-16 | 2012-07-11 | 中国科学院上海药物研究所 | Preparing method of iPS cell and medium for preparing iPS cell |
KR102426327B1 (en) | 2011-11-04 | 2022-08-01 | 메모리얼 슬로안 케터링 캔서 센터 | Midbrain dopamine (da) neurons for engraftment |
AU2014256876B2 (en) | 2013-04-26 | 2020-11-12 | Cornell, University | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells |
SG11201603045VA (en) * | 2013-11-01 | 2016-05-30 | Janssen Biotech Inc | Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2206724A1 (en) | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
JP2008099662A (en) * | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | Method for culturing stem cell |
EP2137296A2 (en) | 2007-03-23 | 2009-12-30 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
EP2314671B1 (en) * | 2008-06-06 | 2022-08-03 | Riken | Method for culture of stem cell |
WO2010137348A1 (en) | 2009-05-29 | 2010-12-02 | Keio University | Method for selecting clone of induced pluripotent stem cells |
ES2590036T3 (en) | 2009-08-12 | 2016-11-17 | Kyoto University | Method for inducing differentiation of pluripotent stem cells into neural precursor cells |
JP5682043B2 (en) * | 2009-09-02 | 2015-03-11 | 国立大学法人京都大学 | How to select pluripotent stem cells safely |
-
2011
- 2011-06-15 US US13/704,584 patent/US8932857B2/en not_active Expired - Fee Related
- 2011-06-15 EP EP11795862.9A patent/EP2582795B1/en not_active Not-in-force
- 2011-06-15 WO PCT/JP2011/064195 patent/WO2011158960A1/en active Application Filing
- 2011-06-15 JP JP2012556312A patent/JP5936134B2/en not_active Expired - Fee Related
Non-Patent Citations (12)
Title |
---|
CHAMBERS S.M. ET AL.: "Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling", NATURE BIOTECHNOLOGY, vol. 27, no. 3, March 2009 (2009-03-01), pages 275 - 280, XP055007827 * |
CUNY G.D. ET AL.: "Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 15, 2008, pages 4388 - 4392, XP023180564 * |
EIRAKU M ET AL.: "Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals", CELL STEM CELL, vol. 3, no. 5, 6 November 2008 (2008-11-06), pages 519 - 532, XP008141935 * |
HAO J. ET AL.: "In Vivo Structure-Activity Relationship Study of Dorsomorphin Analogues Identifies Selective VEGF and BMP Inhibitors", ACS CHEMICAL BIOLOGY, vol. 5, no. 2, February 2010 (2010-02-01), pages 245 - 253, XP008165647 * |
MINOWA T. ET AL.: "Increase in tumor permeability following TGF-beta type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI", BRITISH JOURNAL OF CANCER, vol. 101, no. 11, 2009, pages 1884 - 1890, XP055073121 * |
MIURA K. ET AL.: "Variation in the safety of induced pluripotent stem cell lines", NATURE BIOTECHNOLOGY, vol. 27, no. 8, August 2009 (2009-08-01), pages 743 - 745, XP008143890 * |
OONUKI M. ET AL.: "Studies of differentiation-resistant cells in human induced-pluripotent stem (iPS) cells", REGENERATIVE MEDICINE, vol. 10, 1 February 2011 (2011-02-01), pages 201, XP008167342 * |
See also references of EP2582795A4 * |
TOJO M. ET AL.: "The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta", CANCER SCIENCE, vol. 96, no. 11, November 2005 (2005-11-01), pages 791 - 800, XP008145321 * |
WADA T ET AL.: "Highly efficient differentiation and enrichment of spinal motor neurons derived from human and monkey embryonic stem cells art. e6722", PLOS ONE, vol. 4, no. 8, August 2009 (2009-08-01), pages 1 - 12, XP055072254 * |
WATANABE K. ET AL.: "A ROCK inhibitor permits survival of dissociated human embryonic stem cells", NAT BIOTECHNOL., vol. 25, no. 6, June 2007 (2007-06-01), pages 681 - 686, XP002458303 * |
YAMANAKA S.: "A fresh look at iPS cells", CELL, vol. 137, no. 1, 3 April 2009 (2009-04-03), pages 13 - 17, XP008148115 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9005975B2 (en) | 2009-05-29 | 2015-04-14 | Kyoto University | Method for selecting clone of induced pluripotent stem cells |
JP2013503603A (en) * | 2009-09-02 | 2013-02-04 | 国立大学法人京都大学 | How to select pluripotent stem cells safely |
US10329534B2 (en) | 2010-03-01 | 2019-06-25 | Janssen Biotech, Inc. | Methods for purifying cells derived from pluripotent stem cells |
CN107988381A (en) * | 2011-07-25 | 2018-05-04 | 国立大学法人京都大学 | The method for screening the multipotential stem cell of induction |
JP2014523735A (en) * | 2011-07-25 | 2014-09-18 | 国立大学法人京都大学 | Method for selecting induced pluripotent stem cells |
CN107988381B (en) * | 2011-07-25 | 2021-05-28 | 国立大学法人京都大学 | Method for screening induced pluripotent stem cells |
US10358628B2 (en) | 2011-12-22 | 2019-07-23 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into single hormonal insulin positive cells |
US11377640B2 (en) | 2011-12-22 | 2022-07-05 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into single hormonal insulin positive cells |
US10344264B2 (en) | 2012-12-31 | 2019-07-09 | Janssen Biotech, Inc. | Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells |
US10377989B2 (en) | 2012-12-31 | 2019-08-13 | Janssen Biotech, Inc. | Methods for suspension cultures of human pluripotent stem cells |
EP2980207A4 (en) * | 2013-03-25 | 2016-09-07 | Found Biomedical Res & Innov | Cell sorting method |
US10072242B2 (en) | 2013-03-25 | 2018-09-11 | Foundation For Biomedical Research And Innovation At Kobe | Cell sorting method |
WO2014200114A1 (en) * | 2013-06-11 | 2014-12-18 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2016090408A1 (en) * | 2014-12-08 | 2016-06-16 | Northern Sydney Local Health District | Compositions and methods for neuronal differentiation of cells |
EP3564385A4 (en) * | 2016-12-27 | 2020-08-12 | Sumitomo Chemical Company, Limited | Evaluation method and selection method for induced pluripotent stem cells, and production method for induced pluripotent stem cells |
Also Published As
Publication number | Publication date |
---|---|
EP2582795A1 (en) | 2013-04-24 |
US8932857B2 (en) | 2015-01-13 |
EP2582795A4 (en) | 2013-12-04 |
JP5936134B2 (en) | 2016-06-15 |
JP2013528356A (en) | 2013-07-11 |
EP2582795B1 (en) | 2017-04-12 |
US20130089870A1 (en) | 2013-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2582795B1 (en) | Method for selecting human induced pluripotent stem cells | |
US20230114089A1 (en) | Method for inducing dopaminergic neuron progenitor cells | |
US20230287342A1 (en) | Method for producing retinal pigment epithelial cells | |
JP7161775B2 (en) | Method for inducing differentiation from intermediate mesoderm cells to renal progenitor cells, and method for inducing differentiation from pluripotent stem cells to renal progenitor cells | |
EP2596096B1 (en) | Method for inducing differentiation of human pluripotent stem cell into intermediate mesoderm cell | |
EP2794860B1 (en) | Method for inducing differentiation of human pluripotent stem cells into intermediate mesoderm cells | |
JP5896421B2 (en) | Differentiation induction method from pluripotent stem cells to skeletal muscle or skeletal muscle progenitor cells | |
EP2980207B1 (en) | Cell sorting method | |
US10626368B2 (en) | Method for inducing cerebral cortex neurons | |
EP2678425B1 (en) | Method for producing dendritic cells from pluripotent stem cells | |
EP3246398B1 (en) | Method for selecting skeletal muscle progenitor cell | |
CA2998096C (en) | Method for producing renal progenitor cells | |
JP7357369B2 (en) | Novel renal progenitor cell marker and method for enriching renal progenitor cells using it | |
WO2014104409A1 (en) | Method for inducing astrocytes | |
WO2012060473A1 (en) | Method of efficiently establishing induced pluripotent stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11795862 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012556312 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13704584 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011795862 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011795862 Country of ref document: EP |